BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 11187916)

  • 21. Repetitive low dose oral methotrexate and intravenous mercaptopurine treatment for patients with lower risk B-lineage acute lymphoblastic leukemia. A Pediatric Oncology Group pilot study.
    Mahoney DH; Camitta BM; Leventhal BG; Shuster JJ; Civin CJ; Ganick DJ; Lauer SJ; Steuber CP; Kamen BA
    Cancer; 1995 May; 75(10):2623-31. PubMed ID: 7736409
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Retrospective study of Dana Farber Consortium Protocol in newly diagnosed Egyptian adolescents and young adults with acute lymphoblastic leukemia: Tanta experience.
    Elashtokhy HEA; Elgohary HE; Eldeep BB; Gaber SM; Elbedewy TA
    J Egypt Natl Canc Inst; 2021 Apr; 33(1):9. PubMed ID: 33826046
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Neuropsychological outcomes from a randomized trial of triple intrathecal chemotherapy compared with 18 Gy cranial radiation as CNS treatment in acute lymphoblastic leukemia: findings from Dana-Farber Cancer Institute ALL Consortium Protocol 95-01.
    Waber DP; Turek J; Catania L; Stevenson K; Robaey P; Romero I; Adams H; Alyman C; Jandet-Brunet C; Neuberg DS; Sallan SE; Silverman LB
    J Clin Oncol; 2007 Nov; 25(31):4914-21. PubMed ID: 17971588
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Retrospective analysis of late intensification therapy with high-dose methotrexate for standard-risk acute lymphoblastic leukemia in childhood (CCLSG-S811 study). The Children's Cancer and Leukemia Study Group.
    Koizumi S; Fujimoto T; Sasaki K; Takeda T; Utsumi J; Mimaya J; Ohta S; Ninomiya T; Takaue Y
    Int J Hematol; 1991 Aug; 54(4):307-13. PubMed ID: 1777605
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Outcomes of a randomized trial of hyperfractionated cranial radiation therapy for treatment of high-risk acute lymphoblastic leukemia: therapeutic efficacy and neurotoxicity.
    Waber DP; Silverman LB; Catania L; Mautz W; Rue M; Gelber RD; Levy DE; Goldwasser MA; Adams H; Dufresne A; Metzger V; Romero I; Tarbell NJ; Dalton VK; Sallan SE
    J Clin Oncol; 2004 Jul; 22(13):2701-7. PubMed ID: 15226337
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Extended intrathecal methotrexate may replace cranial irradiation for prevention of CNS relapse in children with intermediate-risk acute lymphoblastic leukemia treated with Berlin-Frankfurt-Münster-based intensive chemotherapy. The Associazione Italiana di Ematologia ed Oncologia Pediatrica.
    Conter V; Aricò M; Valsecchi MG; Rizzari C; Testi AM; Messina C; Mori PG; Miniero R; Colella R; Basso G
    J Clin Oncol; 1995 Oct; 13(10):2497-502. PubMed ID: 7595699
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Current results of studies of immunophenotype-, age- and leukocyte-based therapy for children with acute lymphoblastic leukemia. The Pediatric Oncology Group.
    Crist W; Shuster J; Look T; Borowitz M; Behm F; Bowman P; Frankel L; Pullen J; Krance R; Steuber P
    Leukemia; 1992; 6 Suppl 2():162-6. PubMed ID: 1578922
    [TBL] [Abstract][Full Text] [Related]  

  • 28. An investigation of toxicities and survival in Hispanic children and adolescents with ALL: Results from the Dana-Farber Cancer Institute ALL Consortium protocol 05-001.
    Kahn JM; Cole PD; Blonquist TM; Stevenson K; Jin Z; Barrera S; Davila R; Roberts E; Neuberg DS; Athale UH; Clavell LA; Laverdiere C; Leclerc JM; Michon B; Schorin MA; Welch JJG; Sallan SE; Silverman LB; Kelly KM
    Pediatr Blood Cancer; 2018 Mar; 65(3):. PubMed ID: 29090520
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Refining risk classification in childhood B acute lymphoblastic leukemia: results of DFCI ALL Consortium Protocol 05-001.
    Vrooman LM; Blonquist TM; Harris MH; Stevenson KE; Place AE; Hunt SK; O'Brien JE; Asselin BL; Athale UH; Clavell LA; Cole PD; Kelly KM; Laverdiere C; Leclerc JM; Michon B; Schorin MA; Sulis ML; Welch JJG; Neuberg DS; Sallan SE; Silverman LB
    Blood Adv; 2018 Jun; 2(12):1449-1458. PubMed ID: 29941458
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Outcome of children and adolescents with Down syndrome treated on Dana-Farber Cancer Institute Acute Lymphoblastic Leukemia Consortium protocols 00-001 and 05-001.
    Athale UH; Puligandla M; Stevenson KE; Asselin B; Clavell LA; Cole PD; Kelly KM; Laverdiere C; Leclerc JM; Michon B; Schorin MA; Sulis ML; Welch JJG; Harris MH; Neuberg DS; Sallan SE; Silverman LB
    Pediatr Blood Cancer; 2018 Oct; 65(10):e27256. PubMed ID: 29878490
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Intensive alternating drug pairs for treatment of high-risk childhood acute lymphoblastic leukemia. A Pediatric Oncology Group pilot study.
    Lauer SJ; Camitta BM; Leventhal BG; Mahoney DH; Shuster JJ; Adair S; Casper JT; Civin CI; Graham M; Kiefer G
    Cancer; 1993 May; 71(9):2854-61. PubMed ID: 8467463
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Impact of Socioeconomic Status on Timing of Relapse and Overall Survival for Children Treated on Dana-Farber Cancer Institute ALL Consortium Protocols (2000-2010).
    Bona K; Blonquist TM; Neuberg DS; Silverman LB; Wolfe J
    Pediatr Blood Cancer; 2016 Jun; 63(6):1012-8. PubMed ID: 26913850
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Antimetabolite-based therapy in childhood T-cell acute lymphoblastic leukemia: a report of POG study 9296.
    Winter SS; Holdsworth MT; Devidas M; Raisch DW; Chauvenet A; Ravindranath Y; Ducore JM; Amylon MD
    Pediatr Blood Cancer; 2006 Feb; 46(2):179-86. PubMed ID: 16007607
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Thromboembolism in children with acute lymphoblastic leukaemia treated on Dana-Farber Cancer Institute protocols: effect of age and risk stratification of disease.
    Athale UH; Siciliano SA; Crowther M; Barr RD; Chan AK
    Br J Haematol; 2005 Jun; 129(6):803-10. PubMed ID: 15953008
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Survival of Mexican Children with Acute Lymphoblastic Leukaemia under Treatment with the Protocol from the Dana-Farber Cancer Institute 00-01.
    Jiménez-Hernández E; Jaimes-Reyes EZ; Arellano-Galindo J; García-Jiménez X; Tiznado-García HM; Dueñas-González MT; Martínez Villegas O; Sánchez-Jara B; Bekker-Méndez VC; Ortíz-Torres MG; Ortíz-Fernández A; Marín-Palomares T; Mejía-Aranguré JM
    Biomed Res Int; 2015; 2015():576950. PubMed ID: 25922837
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The low incidence of secondary acute myelogenous leukaemia in children and adolescents treated with dexrazoxane for acute lymphoblastic leukaemia: a report from the Dana-Farber Cancer Institute ALL Consortium.
    Vrooman LM; Neuberg DS; Stevenson KE; Asselin BL; Athale UH; Clavell L; Cole PD; Kelly KM; Larsen EC; Laverdière C; Michon B; Schorin M; Schwartz CL; Cohen HJ; Lipshultz SE; Silverman LB; Sallan SE
    Eur J Cancer; 2011 Jun; 47(9):1373-9. PubMed ID: 21514146
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The frequency and management of asparaginase-related thrombosis in paediatric and adult patients with acute lymphoblastic leukaemia treated on Dana-Farber Cancer Institute consortium protocols.
    Grace RF; Dahlberg SE; Neuberg D; Sallan SE; Connors JM; Neufeld EJ; Deangelo DJ; Silverman LB
    Br J Haematol; 2011 Feb; 152(4):452-9. PubMed ID: 21210774
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Improvement in treatment of childhood acute lymphoblastic leukemia: a 10-year study by the Children's Cancer and Leukemia Study Group.
    Koizumi S; Fujimoto T
    Int J Hematol; 1994 Feb; 59(2):99-112. PubMed ID: 8018909
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effectiveness of rubidomycin in induction therapy with vincristine, prednisone, and L-asparaginase for standard risk childhood acute lymphocytic leukemia: results of a Dutch phase III study (ALL V). A report on behalf of the Dutch Childhood Leukemia Study Group (DCLSG).
    van der Does-van den Berg A; van Wering ER; Suciu S; Solbu G; van 't Veer MB; Rammeloo JA; de Koning J; van Zanen GE
    Am J Pediatr Hematol Oncol; 1989; 11(2):125-33. PubMed ID: 2665546
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Health Status and Health-related Quality of Life Measurement in Pediatric Cancer Clinical Trials: An Examination of the DFCI 00-01 Acute Lymphoblastic Leukemia Protocol.
    Rae C; Furlong W; Feeny D; Couchman R; Silverman L; Sallan S; Laverdiere C; Clavell L; Michon B; Kelly K; Larsen E; Pullenayegum E; Athale U; Barr R
    J Pediatr Hematol Oncol; 2018 Nov; 40(8):580-587. PubMed ID: 29901560
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.